Is IDH mutation status associated with ¹⁸F-FDopa PET uptake?

Timothée Zaragori^{1

2}, Eric Guedj^{3

4

5}, Antoine Verger^{6

7}

Affiliations

¹ Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France. timothee.zaragori@univ-lorraine.fr.
² IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France. timothee.zaragori@univ-lorraine.fr.
³ Department of Nuclear Medicine, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Timone University Hospital, 13000, Marseille, France.
⁴ CERIMED, Aix-Marseille Université, 13000, Marseille, France.
⁵ Aix-Marseille Université, CNRS, Ecole Centrale de Marseille, UMR 7249, Institut Fresnel, 13000, Marseille, France.
⁶ Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.
⁷ IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France.

Comment

Timothée Zaragori et al. Ann Nucl Med. 2020 Mar.

. 2020 Mar;34(3):228-229.

doi: 10.1007/s12149-020-01442-1. Epub 2020 Jan 30.

Timothée Zaragori^{1

2}, Eric Guedj^{3

4

5}, Antoine Verger^{6

7}

¹ Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France. timothee.zaragori@univ-lorraine.fr.
² IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France. timothee.zaragori@univ-lorraine.fr.
³ Department of Nuclear Medicine, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Timone University Hospital, 13000, Marseille, France.
⁴ CERIMED, Aix-Marseille Université, 13000, Marseille, France.
⁵ Aix-Marseille Université, CNRS, Ecole Centrale de Marseille, UMR 7249, Institut Fresnel, 13000, Marseille, France.
⁶ Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.
⁷ IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France.

No abstract available

Comment in

Reply to Zaragori et al.: "Is IDH mutation status associated with ¹⁸F-FDopa PET uptake".
Cicone F, Carideo L, Scaringi C, Minniti G. Cicone F, et al. Ann Nucl Med. 2020 Mar;34(3):230-231. doi: 10.1007/s12149-020-01443-0. Ann Nucl Med. 2020. PMID: 32020507 No abstract available.

¹⁸F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G. Cicone F, et al. Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3. Ann Nucl Med. 2019. PMID: 30607877